Biochemistry, Genetics and Molecular Biology
Cancer Cell
100%
Neurotensin
73%
Colon
61%
Catenin
59%
Regulatory Mechanism
55%
Protein
47%
Cellular Differentiation
46%
Apoptosis
43%
Wnt Signaling Pathway
43%
Fatty Acid Synthase
43%
Gene
38%
Secretion (Process)
30%
Fatty Acid
28%
Cell Proliferation
26%
Growth
26%
Signal Transduction
26%
Tumor Progression
25%
Carcinogenesis
25%
AMP-activated Protein Kinase
22%
Survival
21%
Mechanistic Target of Rapamycin
20%
Upregulation
20%
Tumor Necrosis Factor
19%
Enzyme
19%
Promoter Region
19%
Ketogenesis
19%
Mammalian Target of Rapamycin
15%
Transcription Factor NFAT
15%
down Regulation
15%
Goblet Cell
15%
Autophagy
15%
Tumor Initiation
15%
Metabolic Pathway
15%
Kinase
14%
Phosphotransferase
14%
Radiation
14%
Phosphoinositide 3-Kinase
14%
Adipocyte
14%
Beta Oxidation
14%
Blood Plasma
13%
Clinical Trial
13%
Homeostasis
13%
Synthase
12%
DNA Damage Response
12%
Messenger RNA
12%
S100A4
12%
Sirtuin
12%
Neuroendocrine Cell
12%
Integrin
12%
Doxorubicin
12%
Medicine and Dentistry
Patient
80%
Neurotensin
51%
Colorectal Carcinoma
49%
Cancer Cell
41%
Therapeutic Procedure
40%
Metastatic Carcinoma
40%
Cells
39%
Malignant Neoplasm
39%
Neoplasm
32%
Cell Differentiation
32%
Analysis
29%
Regulatory Mechanism
26%
Neuroendocrine Tumor
25%
Secretion (Process)
21%
Breast Cancer
21%
Development
20%
Growth
19%
Diseases
18%
Differentiation
18%
Triple Negative Breast Cancer
18%
Gene
18%
Signal Transduction
17%
Fatty Acid Synthase
16%
Carcinogenesis
15%
Survival
15%
Goblet Cell
15%
Mechanistic Target of Rapamycin
15%
Therapeutics
15%
Programmed Cell Death
14%
Adverse Event
13%
Cell Proliferation
13%
Protein
13%
Catenin
13%
Hydroxymethylglutaryl Coenzyme A Reductase Kinase
13%
Glioblastoma
13%
Phosphotransferase
13%
Overall Survival
12%
Estrogen Receptor Positive Breast Cancer
12%
Tumor Invasion
12%
Diet Induced Obesity
12%
Transcription Factor NFAT
12%
Ras
12%
Synthetase
12%
Non Small Cell Lung Cancer
12%
Mammalian Target of Rapamycin
12%
Lung Cancer
11%
Adjuvant Therapy
11%
Association
11%
Clinical Trial
11%
Tumor Progression
11%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
78%
Colorectal Carcinoma
64%
Neoplasm
51%
Neurotensin
44%
Metastasis
36%
Apoptosis
32%
Neuroendocrine Tumor
31%
Survival
22%
Triple Negative Breast Cancer
19%
Catenin
19%
Protein
18%
Clinical Trial
17%
Adverse Event
17%
Tumor Growth
17%
Carcinoid
16%
Fatty Acid Synthase
16%
Breast Cancer
16%
Cancer of Unknown Primary Site
15%
DNA
15%
Tumor Necrosis Factor
15%
Hydroxymethylglutaryl Coenzyme A Reductase Kinase
14%
Colon Carcinoma
14%
Mammalian Target of Rapamycin
14%
Fatty Acid
13%
Nanoparticle
13%
Enzymes
13%
Disease
13%
Inflammation
12%
Estrogen Receptor Positive Breast Cancer
12%
Nanocrystal
12%
Paclitaxel
12%
Sorafenib
12%
Non Small Cell Lung Cancer
12%
Glioblastoma
12%
Integrin
12%
Doxorubicin
12%
Overall Survival
11%
Toxicity
11%
Prognosis
11%
Chemotherapy
10%
Phase II Trials
10%
Radiosensitizing Agent
10%
Combination Therapy
10%
Phosphatidylinositol 3 Kinase
9%
Mouse Model
9%
Lung Metastasis
8%
Carcinogenesis
8%
Progression Free Survival
8%
Tamoxifen
8%
Vasculotropin Receptor 2
8%
